Last reviewed · How we verify
MAL Vehicle Cream
MAL Vehicle Cream is a Small molecule drug developed by Galderma R&D. It is currently in Phase 3 development for Topical delivery vehicle for dermatological applications (specific indication dependent on active ingredient formulated with this vehicle).
MAL Vehicle Cream is a topical formulation vehicle designed to deliver active pharmaceutical ingredients through the skin for localized therapeutic effect.
MAL Vehicle Cream is a topical formulation vehicle designed to deliver active pharmaceutical ingredients through the skin for localized therapeutic effect. Used for Topical delivery vehicle for dermatological applications (specific indication dependent on active ingredient formulated with this vehicle).
At a glance
| Generic name | MAL Vehicle Cream |
|---|---|
| Sponsor | Galderma R&D |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
As a vehicle cream, this formulation serves as the delivery system or base for active pharmaceutical agents rather than being a drug with its own mechanism of action. The cream base facilitates penetration and absorption of incorporated active ingredients through the stratum corneum and into deeper skin layers. The specific therapeutic mechanism depends on the active pharmaceutical ingredient combined with this vehicle.
Approved indications
- Topical delivery vehicle for dermatological applications (specific indication dependent on active ingredient formulated with this vehicle)
Common side effects
Key clinical trials
- A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study (PHASE3)
- Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face (PHASE3)
- Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy (PHASE3)
- Efficacy of Methyl Aminolevulinate + Daylight in Patients With Facial Photodamage (PHASE2)
- Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT) (PHASE2)
- Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MAL Vehicle Cream CI brief — competitive landscape report
- MAL Vehicle Cream updates RSS · CI watch RSS
- Galderma R&D portfolio CI
Frequently asked questions about MAL Vehicle Cream
What is MAL Vehicle Cream?
How does MAL Vehicle Cream work?
What is MAL Vehicle Cream used for?
Who makes MAL Vehicle Cream?
What development phase is MAL Vehicle Cream in?
Related
- Manufacturer: Galderma R&D — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Topical delivery vehicle for dermatological applications (specific indication dependent on active ingredient formulated with this vehicle)
- Compare: MAL Vehicle Cream vs similar drugs
- Pricing: MAL Vehicle Cream cost, discount & access